Miguel Martin is an Associated Consultant in Clinical Biochemistry, working at the Biochemistry and Clinical Genetics Departments of the '12 de Octubre' University Hospital, Madrid (Spain). His research focuses on the biochemical and molecular genetic basis of mitochondrial OXPHOS diseases, metabolic myopathies, and exercise intolerance disorders (particularly McArdle's disease). He leads the Mitochondrial and Neuromuscular Diseases Group at the 12 de Octubre Health Research Institute (i+12), a multidisciplinary group of clinicians, biochemists, geneticists, and molecular biologists. This group belongs to the CIBER for Rare Diseases (ISCIII), where Miguel was the Coordinator of the Mitochondrial Medicine Program for 5 years. Since 2015, he coordinates the Translational Research Laboratories Section of i+12. This group belongs to the National Reference Units (CSURs) of Metabolic Hereditary Disorders, Neuromuscular Disorders, as well as the European Reference Network Metab-ERN. Since 2005, Miguel has been the PI of consecutive projects from the Health Strategy Action of ISCIII. He participated in an EU project aimed to build a registry of metabolic myopathies, and in several collaborative initiatives of the Biosciences Group's Action of the Community of Madrid. He has directed and co-directed seven doctoral theses and tutored several PhD students, post-doc researchers (Sara Borrell), and post-MIR/FSE researchers from ISCIII calls.